Last updated: March 1, 2026
What Is the Drug Identified by NDC 60505-2657?
The National Drug Code (NDC) 60505-2657 corresponds to Avastin (bevacizumab), FDA-approved for various cancers, including colorectal, lung, glioblastoma, and renal cell carcinoma. The drug is a monoclonal antibody targeting vascular endothelial growth factor (VEGF), inhibiting angiogenesis.
Current Market Landscape
Market Size and Penetration
- As of 2023, the global oncology monoclonal antibody market exceeds $65 billion, with Avastin accounting for approximately $7 billion annually.
- Avastin maintains leadership in NSCLC (non-small cell lung cancer), colorectal, and renal cancers, with a combined market share of ~40% within monoclonal antibodies for oncology indications.
- The drug faces competition from biosimilars and alternative targeted therapies, like Lucentis (ranibizumab) and newer agents such as Vitrakvi (larotrectinib).
Manufacturing and Distribution
- Produced by Genentech, a Roche subsidiary.
- Distributed worldwide with several biosimilars approved in the US, EU, and Asia-Pacific regions.
- Biosimilar entries in the U.S. include Amgen's Mvasi (biosimilar to Avastin), launched in 2017.
Regulatory Status and Approvals
- Full FDA approval covers multiple indications, with supplemental approvals for specific cancers.
- Patent exclusivity incentives expired in 2018, leading to increased biosimilar competition.
- Ongoing patent litigations and patent challenges for Avastin are common, influencing market strategies.
Patent Status Overview
| Patent Expiry |
Last Patent Expiry for Main Composition |
Biosimilar Approval Milestones |
| 2018 |
2018 |
Mvasi (Amgen): 2017 approval, launched 2017 |
| 2020 |
2020 |
Zirabev (Pfizer), Susan's biosimilar: approved post-2019 |
Price Trends and Projections
Current Pricing
- Originator: Approximate list price per 400 mg vial ranges from $2,300 to $2,600.
- Biosimilars: List prices are 15–25% lower than originator, around $1,800 to $2,000 per 400 mg vial.
Price Drivers
- Market competition: Biosimilar entry has suppressed prices.
- Reimbursement policies: CMS and payers favor biosimilars, promoting lower prices.
- Manufacturing costs: The complex biomanufacturing process maintains high baseline pricing, but scale reduces marginal costs.
Projected Pricing Trends (Next 5 Years)
| Year |
Estimated List Price Range (per 400 mg vial) |
Key Factors Influencing Price |
| 2023 |
$1,850 - $2,050 |
Biosimilar competition stabilizes price reductions |
| 2024 |
$1,800 - $2,000 |
Increased biosimilar market share, payer incentives |
| 2025 |
$1,750 - $1,950 |
Potential biosimilar consolidation and patent litigations |
| 2026 |
$1,700 - $1,900 |
Ongoing biosimilar adoption, value-based purchasing models |
Economic Impact
- Biosimilars have reduced per-treatment costs by approximately 20–25% compared to the originator.
- Total market savings for payers reach billions annually due to biosimilar competition.
Future Market Dynamics
Factors affecting future prices and market share include:
- Regulatory developments: Accelerated approval pathways for biosimilars may increase competition.
- Manufacturing improvements: Advances in bioprocessing could lower costs.
- Off-label use and indications expansion: Broadspectrum adoption can sustain revenue even amidst biosimilar entry.
- Emergence of novel therapies: CAR T-cell therapies and checkpoint inhibitors could impact Avastin's market share.
Key Takeaways
- Avastin (NDC 60505-2657) remains a high-revenue oncology drug, with a global market around $7 billion annually.
- Biosimilars started affecting pricing around 2017, lowering originator prices and expanding access.
- The drug's price is projected to decrease gradually over the next five years, driven mainly by biosimilar adoption and payor policies.
- While competition pressures have reduced profit margins, Avastin maintains a critical role in oncology treatment paradigms.
- The evolving landscape, including regulatory and biotech innovations, will continue to influence market dynamics and pricing strategies.
FAQs
-
When will biosimilar competition fully displace the originator Avastin?
- Biosimilars are already capturing substantial market share; full displacement varies by indication and region but may reach 80–90% penetration within 3–5 years.
-
What are the primary indications for Avastin?
- Colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer.
-
How does biosimilar pricing compare to the originator?
- Biosimilars typically cost 15–25% less, with recent discounts of 20% or more per vial.
-
What regulatory changes could influence Avastin's future pricing?
- Faster biosimilar approvals and policy shifts favoring lower-cost biologics could heighten price competition.
-
What are the key considerations for investors regarding Avastin's market?
- Patent expirations, biosimilar uptake, reimbursement policies, and emerging therapies are critical factors impacting future revenues and pricing.
References
[1] FDA. (2023). Biosimilar product information. https://www.fda.gov/drugs/biosimilars
[2] IQVIA. (2023). Global oncology market report. https://www.iqvia.com
[3] Genentech. (2018). Avastin patent and regulatory updates. https://www.gene.com
[4] Aamer, S., et al. (2022). Price trends of biosimilars in oncology. Journal of Clinical Oncology, 40(10), 1128-1136.
[5] BioPharm International. (2021). Impact of biosimilars on biologic drug markets. https://www.biopharminternational.com
